Articles

Videos

Podcasts

Clinical

Patients with COVID-19 who were vaccinated against the flu were found to be significantly less likely to visit the emergency department and be admitted to the intensive care unit.

Study Indicates Flu Shot May Protect Against Severe Effects of COVID-19 

On average, those who received a flu-like diagnosis changed their cell phone usage behavior 1 day before their diagnosis and the 2 to 4 days afterward.

Anonymous Cell Phone Metadata May Show Changes in Behavior Associated With Flu-Like Illness

Uncertainty and preparedness make strange bedfellows.

Into the Unknown: What Might a Combined Influenza/COVID-19 Season Look Like This Fall?

Kevin Day, PharmD, president of Day’s Miami Heights Pharmacy in Cincinnati, Ohio, discusses how his independent pharmacy is gearing up for influenza season while continuing to deliver COVID-19 vaccines safely.

Leveling Up for Flu Season in the COVID-19 Era: How One Pharmacy Is Rising to the Challenge

Since the start of the pandemic, politicization and misinformation have led to hesitancy about the COVID-19 vaccine. However, vaccine hesitancy is not a new behavior.

Just One More Shot: Influenza Vaccine Hesitancy During a Pandemic

The COVID-19 pandemic has led to increased vigilance over the proper disposal of vaccine-related materials, such as vials, needles, syringes, and bandages.

Where's All This Waste Going? The Environmental Impact of Vaccinations in the Time of COVID-19

Individuals with COVID-19 who had not had a flu shot were up to 20% more likely to be admitted to the ICU and were up to 58% more likely to visit the emergency department.

Study Finds Flu Shots Protect Against Some Severe COVID-19 Symptoms

As COVID-19 vaccination efforts continue, it is more important than ever for pharmacists to be equipped with the knowledge and resources to bust the myths surrounding vaccinations, particularly in preparation for the upcoming influenza season, which is expected to occur from October 2021 to May 2022.

Equal but Not the Same—2021 Update on Influenza Vaccines

The study plans to enroll approximately 180 participants to evaluate the safety, reactogenicity, and immunogenicity of its quadrivalent seasonal influenza mRNA vaccine in adults 18 years and older. 

First Participant Dosed in Phase 1/2 Study of Moderna’s Quadrivalent Seasonal Flu mRNA Vaccine

While the exact reason for the decreased immune response in middle-aged adults remains unclear, these findings suggest that this patient population may be continuously susceptible to the 3c2A H3N2 infection, even with immunization. 